Ologen-Augmentation of Ahmed Valves in Pediatric Glaucomas: 2- to 6-Year Follow-Up.

IF 3.2 Q2 Medicine

Ophthalmology. Glaucoma Pub Date : 2025-06-27 DOI:10.1016/j.ogla.2025.06.008

Adam Jacobson, Brenda L Bohnsack

{"title":"Ologen-Augmentation of Ahmed Valves in Pediatric Glaucomas: 2- to 6-Year Follow-Up.","authors":"Adam Jacobson, Brenda L Bohnsack","doi":"10.1016/j.ogla.2025.06.008","DOIUrl":null,"url":null,"abstract":"Purpose: Determine 2- to 6-year outcomes of Ologen augmentation of Ahmed glaucoma devices (OAGDs) in children with glaucoma.Design: Retrospective interventional case series.Subjects: Children (<18 years of age) with glaucoma requiring surgery for intraocular pressure (IOP) control with at least 2 years of postoperative follow-up.Methods: Placement of OAGD between 2018 and 2022.Main outcome measures: Change in IOP, number of glaucoma medications and best-corrected visual acuity from preoperative to final follow-up, and success of surgery (complete defined as IOP 5 to 20 mmHg without additional medications, visually devastating complication or additional IOP-lowering surgeries, qualified success defined as above except IOP control was maintained ± glaucoma medications).Results: Forty eyes of 28 patients underwent OAGD at median age of 2.6 years (interquartile range [IQR], 0.6-7.8). Primary congenital glaucoma was the most common diagnosis (12 eyes of 9 patients), followed by glaucoma secondary to nonacquired ocular anomaly (11 eyes of 6 patients). Twenty-two eyes of 16 patients had prior glaucoma surgery (median 2, [interquatile range (IQR), 1-2]). Preoperative IOP was a median of 27 mmHg (IQR, 24-35) on a median of 3 (IQR, 2-3) glaucoma medications. At final follow-up (median 3.6 years [IQR, 2.9-4.3]), IOP (median, 15 mmHg [IQR, 13-17]) and glaucoma medications (median, 0 [IQR, 0-0]) were significantly decrease (P < 0.0001). Complete success at final follow-up was 55% (22 of 40 eyes) with 3- and 5-year survival rates of 75% (95% confidence interval [CI], 59-86) and 57% (95% CI, 35-74). Qualified success rate was 75% (30 of 40 eyes) with 3- and 5-year survival rates of 87% (95% CI, 71-95) and 67% (95% CI, 42-83), respectively.Conclusions: Although OAGD decreased IOP and the number of glaucoma medications, the high survival rates seen over the first 3 years decreased by 5 years.Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.","PeriodicalId":56368,"journal":{"name":"Ophthalmology. Glaucoma","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology. Glaucoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ogla.2025.06.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Determine 2- to 6-year outcomes of Ologen augmentation of Ahmed glaucoma devices (OAGDs) in children with glaucoma.

Design: Retrospective interventional case series.

Subjects: Children (<18 years of age) with glaucoma requiring surgery for intraocular pressure (IOP) control with at least 2 years of postoperative follow-up.

Methods: Placement of OAGD between 2018 and 2022.

Main outcome measures: Change in IOP, number of glaucoma medications and best-corrected visual acuity from preoperative to final follow-up, and success of surgery (complete defined as IOP 5 to 20 mmHg without additional medications, visually devastating complication or additional IOP-lowering surgeries, qualified success defined as above except IOP control was maintained ± glaucoma medications).

Results: Forty eyes of 28 patients underwent OAGD at median age of 2.6 years (interquartile range [IQR], 0.6-7.8). Primary congenital glaucoma was the most common diagnosis (12 eyes of 9 patients), followed by glaucoma secondary to nonacquired ocular anomaly (11 eyes of 6 patients). Twenty-two eyes of 16 patients had prior glaucoma surgery (median 2, [interquatile range (IQR), 1-2]). Preoperative IOP was a median of 27 mmHg (IQR, 24-35) on a median of 3 (IQR, 2-3) glaucoma medications. At final follow-up (median 3.6 years [IQR, 2.9-4.3]), IOP (median, 15 mmHg [IQR, 13-17]) and glaucoma medications (median, 0 [IQR, 0-0]) were significantly decrease (P < 0.0001). Complete success at final follow-up was 55% (22 of 40 eyes) with 3- and 5-year survival rates of 75% (95% confidence interval [CI], 59-86) and 57% (95% CI, 35-74). Qualified success rate was 75% (30 of 40 eyes) with 3- and 5-year survival rates of 87% (95% CI, 71-95) and 67% (95% CI, 42-83), respectively.

Conclusions: Although OAGD decreased IOP and the number of glaucoma medications, the high survival rates seen over the first 3 years decreased by 5 years.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

查看原文本刊更多论文

儿童青光眼艾哈迈德瓣膜的olog增强：2-6年随访。

目的：确定Ahmed青光眼装置（OAGD）的ogen增强治疗儿童青光眼的2 - 6年预后。设计：回顾性介入病例系列研究对象：需要手术控制IOP（眼内压）的青光眼儿童（小于10岁），术后随访至少2年。方法：2018 - 2022年间放置OAGD。主要观察指标：术前至最终随访期间IOP的变化，青光眼药物的数量和最佳矫正视力（BCVA），手术成功(完全定义为IOP 5- 20mmhg，无额外药物，视力破坏性并发症或额外的降低眼压手术，除维持眼压控制外，上述定义的合格成功±青光眼药物。结果：28例患者40眼发生OAGD，中位年龄2.6岁[IQR 0.6, 7.8]。原发性先天性青光眼是最常见的诊断（9例12眼），其次是继发于非获得性眼部异常的青光眼（6例11眼）。16例患者中22只眼既往有青光眼手术史（中位数2，[IQR 1,2]）。术前使用中位数3 [IQR 2,3]青光眼药物，IOP中位数为27 mmHg [IQR 24,35]。在最终随访（中位随访3.6年[IQR 2.9, 4.3]）时，IOP（中位随访15 mmHg [IQR 13,17]）和青光眼药物治疗（中位随访0 [IQR 0,0]）均显著降低(p结论：OAGD降低了IOP和青光眼药物治疗的数量，前3年的高生存率下降了5年。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology. Glaucoma Medicine-Medicine (all)

CiteScore

4.20

自引率

0.00%

发文量

140